Sign in

CIK 0001714899 · Large accelerated filer

Denali Therapeutics Inc.

Sign in to watch
Ticker
DNLI
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Incorporated
DE
Entity type
operating
EIN
463872213
Phone
(650) 866-8547
Business address
161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA, 94080
  1. 10-Q Report Quarterly Report
  2. 8-K Event Results of operations
  3. 8-K Event Material agreement · Other events
  4. 424B5 Offering Prospectus
  5. 8-K Event Results of operations · Other events
  6. 424B5 Offering Prospectus
  7. 4 Option exercise COFO and Secretary acquired 20,000 shares (option exercise)
  8. 4 Open-market sale Director sold 20,000 shares at an average $30.82 ($616,304)
  9. 4 Open-market sale Director sold 20,000 shares at an average $31.61 ($632,282)
  10. 4 Open-market sale Chief Medical Officer sold 2,424 shares at $31.98 ($77,520)
  11. 4 Open-market sale President and CEO sold 2,404 shares at $33.22 ($79,861)
  12. 4 Open-market sale Director sold 2,253 shares at $33.22 ($74,845)
  13. 4 Open-market sale COFO and Secretary sold 2,576 shares at $33.22 ($85,575)
  14. 4 Open-market sale Chief Medical Officer sold 2,576 shares at $33.22 ($85,575)
  15. 4 Grant or award Chief Medical Officer acquired 22,500 shares (grant or award)
  16. 4 Grant or award COFO and Secretary acquired 22,500 shares (grant or award)
  17. 10-Q Report Quarterly Report
  18. 8-K Event Results of operations
  19. 4 Open-market sale Director sold 20,000 shares at an average $35.61 ($712,110)
  20. 4 Option exercise Director acquired 62,500 shares (option exercise)

Page 18 of 40 · 789 filings